Literature DB >> 26921762

Predictability of lesion durability for AF ablation using phased radiofrequency: Power, temperature, and duration impact creation of transmural lesions.

Mélèze Hocini1, Cathy Condie2, Mark T Stewart2, Nicole Kirchhof2, Jason D Foell2.   

Abstract

BACKGROUND: Long-term clinical outcomes for atrial fibrillation ablation depend on the creation of durable transmural lesions during pulmonary vein isolation and on substrate modification. Focal conventional radiofrequency (RF) ablation studies have demonstrated that tissue temperature and power are important factors for lesion formation. However, the impact and predictability of temperature and power on contiguous, transmural lesion formation with a phased RF system has not been described.
OBJECTIVE: The purpose of this study was to determine the sensitivity, specificity, and predictability of power and temperature to create contiguous, transmural lesions with the temperature-controlled, multielectrode phased RF PVAC GOLD catheter.
METHODS: Single ablations with the PVAC GOLD catheter were performed in the superior vena cava of 22 pigs. Ablations from 198 PVAC GOLD electrodes were evaluated by gross examination and histopathology for lesion transmurality and contiguity. Lesions were compared to temperature and power data from the phased RF GENius generator. Effective contact was defined as electrodes with a temperature of ≥50°C and a power of ≥3 W.
RESULTS: Eighty-five percent (168 of 198) of the lesions were transmural and 79% (106 of 134) were contiguous. Electrode analysis showed that >30 seconds of effective contact identified transmural lesions with 85% sensitivity (95% confidence interval [CI] 78%-89%), 93% specificity (95% CI 76%-99%), and 99% positive predictive value (95% CI 94%-100%). Sensitivity for lesion contiguity was 95% (95% CI 89%-98%), with 62% specificity (95% CI 42%-78%) and 90% positive predictive value (95% CI 83%-95%). No char or coagulum was observed on the catheter or tissue.
CONCLUSION: PVAC GOLD safely, effectively, and predictably creates transmural and contiguous lesions.
Copyright © 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ablation; Atrial fibrillation; Contiguous; Lesion; PVAC GOLD; Pulmonary vein isolation; Radiofrequency; Transmural

Mesh:

Year:  2016        PMID: 26921762     DOI: 10.1016/j.hrthm.2016.02.012

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  5 in total

1.  A 5-year clinical follow-up after duty-cycled phased RF ablation of paroxysmal atrial fibrillation.

Authors:  Antoine Lepillier; Xavier Copie; Gilles Lascault; Olivier Paziaud; Olivier Piot
Journal:  J Interv Card Electrophysiol       Date:  2016-11-22       Impact factor: 1.900

2.  Choice of Steerable Sheath Impacts Contact Force Stability During Pulmonary Vein Isolation.

Authors:  Evan Hiner; Dipak P Shah
Journal:  J Innov Card Rhythm Manag       Date:  2021-12-15

3.  The Incidence, Electrophysiological Characteristics and Ablation Outcome of Left Atrial Tachycardias after Pulmonary Vein Isolation Using Three Different Ablation Technologies.

Authors:  Patrick Leitz; Kristina Wasmer; Christian Andresen; Fatih Güner; Julia Köbe; Benjamin Rath; Florian Reinke; Julian Wolfes; Philipp S Lange; Christian Ellermann; Gerrit Frommeyer; Lars Eckardt
Journal:  J Cardiovasc Dev Dis       Date:  2022-02-03

4.  Pulmonary vein isolation using multi-electrode radiofrequency vs conventional point-by-point radiofrequency ablation: A meta-analysis of randomized and non-randomized studies.

Authors:  Dursun Aras; Serkan Topaloglu; Serkan Cay; Ozcan Ozeke; Firat Ozcan; Goksel Cagirci
Journal:  Indian Pacing Electrophysiol J       Date:  2017-02-20

5.  Paroxysmal and persistent atrial fibrillation ablation outcomes with the pulmonary vein ablation catheter GOLD duty-cycled phased radiofrequency ablation catheter: quality of life and 12-month efficacy results from the GOLD Atrial Fibrillation Registry.

Authors:  Lucas Boersma; Edward Koźluk; Giampiero Maglia; João de Sousa; Olaf Grebe; Lars Eckardt; Robert B Hokanson; Lauren A Hemingway; Ekaterina Ostern; Hyoung-Seob Park; Giovanni Rovaris; Fernando Arribas; Christoph Scharf; Zoltán Csanádi; Ángel Arenal; Francesco Laurenzi; Martijn Klaver; Andreas Goette
Journal:  Europace       Date:  2020-06-01       Impact factor: 5.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.